GlassScriptPhysician profile
Nishat Fatima
NPI 1760898936
$1,356.73
in general payments reported to CMS, 2019-2025
17 companies · $25.56 in 2025
The $25.56 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $150 · 2021: $221 · 2022: $769 · 2023: $59.59 · 2025: $25.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $85.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $85.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $467.35 | 2019-2023 | Sogroya |
| Abbott Laboratories | $216.27 | 2019-2022 | |
| Corcept Therapeutics | $108.40 | 2021-2022 | |
| Lilly USA, LLC | $106.04 | 2019-2022 | |
| Dexcom, INC. | $103.69 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $84.71 | 2020-2022 | |
| Insulet Corporation | $55.32 | 2022 | |
| Radius Health, INC. | $31.79 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $31.43 | 2020 | |
| Sanofi-Aventis U.S. LLC | $30.44 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $26.77 | 2022 | |
| Xeris Pharmaceuticals, INC. | $25.56 | 2025 | Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.82 | 2020 | |
| Merck Sharp & Dohme LLC | $14.48 | 2019 | |
| Abbvie INC. | $14.23 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $12.50 | 2020 | |
| Amgen INC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nishat Fatima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.